Perioperative Treatment in Resectable Gastric Cancer With Spartalizumab (PDR001) in Combination With Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel (FLOT)
Multicenter, open-label, non randomized, phase 2 trial in resectable gastric or gastroesophageal junction adenocarcinoma: Perioperative Treatment by Spartalizumab (PDR001) in Combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT)
Gastric Cancer by AJCC V8 Stage|Resectable Carcinoma
DRUG: perioperative treatment
Pathologic response after pre-operative treatment, Proportion of patients with pCR (pathologic complete response) in the primary tumour defined as: no tumour residue found in the tissue collected during the surgery evaluated by the pathologist, At surgery, an average 3 months after treatment initiation
Evaluate the impact of perioperative treatment on disease-free survival, Disease-free survival (DFS) defined as time between inclusion and first disease progression, Through study completion, an average of 5 follow-up year|Evaluate the impact of perioperative treatment on overall survival, Overall survival (OS) defined as the time between inclusion and death whatever cause;, Up to death|The correlation between pathologic Complete response and survival outcomes (disease-free and overall survival), Proportion of patients with margin-free resection (R0), defined as a microscopically margin-negative resection, in which no gross or microscopic tumor remains in the primary tumor bed, At surgery, an average 3 months after treatment initiation|Treatment-Related Adverse Events, Type, grade and number of Adverse Events as Assessed by CTCAE v5.0, Toxicities occurring up to 1 month after the end of treatment
Multicenter, open-label, non randomized, phase 2 trial in resectable gastric or gastroesophageal junction adenocarcinoma: Perioperative Treatment by Spartalizumab (PDR001) in Combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT)